Semaglutide Patent Expiry: A US$6 Billion Opportunity for Indian Pharma

For nearly a decade, the world’s hottest drug category sat behind a moat of patents. That moat just lost its first major brick. On 20 March 2026, Novo Nordisk’s faces semaglutide patent expiry in India. By the following Monday, more than five domestic manufacturers had launched generic versions, several at price points 70 to 90 percent below the innovator. By the end of April, the count had crossed 40 brands. Sell-side desks are now sizing the cumulative Indian pharma opportunity at over Rs. 50,000 crore — roughly US$6 billion — once the domestic market, neighbouring emerging economies, and a small but lucrative set of regulated geographies are added together. Whether the full number lands will depend on a lot of moving parts. The direction of travel does not.

What Makes Semaglutide So Valuable?

Semaglutide belongs to a class called GLP-1 receptor agonists. The molecule mimics a gut hormone that does two useful things at once. It nudges the pancreas to release more insulin and signals to the brain that the body has had enough food. That dual action made it a workhorse for type 2 diabetes. The weight-loss effect, initially a footnote in trial files, turned it into a household name.

The financials are extraordinary even by big-pharma standards. Combined Ozempic and Wegovy sales crossed $26 billion in 2024, growing at around 40 percent a year. Eli Lilly’s rival tirzepatide added another $16 billion. As reported by Business Today, the global GLP-1 category is being modelled at $150 billion annually by the end of this decade — a number larger than India’s entire pharmaceutical industry today.

Why the Window Opens Earlier in India?

The United States and Europe will keep semaglutide protected until 2031–2032. India sits on the early end of expiries, and that is not an accident. Section 3(d) of the Indian Patents Act sets a higher bar for what counts as a patentable incremental innovation, which historically has shut the door on the kind of patent-term extensions Western jurisdictions allow. The core composition patent fell here in late 2024. The formulation and delivery patents lapsed in March 2026.

For Indian manufacturers, this is more than a head start in the home market. It is a six-year runway to scale peptide manufacturing, validate cold chains, file dossiers in dozens of geographies, and accumulate post-marketing data — all before the much larger US market eventually opens up.

Sizing the US$6 Billion Number

The headline figure stitches together three separate revenue pools.

The domestic pool is the obvious one. According to Pharmarack data, GLP-1 sales in India were already growing 178 percent year-on-year in February 2026, taking moving annual turnover to Rs.14.46 billion. Sheetal Sapale, vice-president (commercial) at Pharmarack, told The Indian Practitioner that monthly unit volumes, running at around 1.2 lakh, could double within three months on the back of generic affordability alone.

The second pool is the regulated markets where semaglutide also goes off patent in 2026. Canada and Brazil, taken together, account for nearly $2 billion of branded semaglutide sales annually. Indian players have been preparing dossiers for both for years.

The third pool is the rest of the emerging world — Asia, Africa, Latin America — where Indian generics already hold meaningful share in adjacent therapy categories.

A January 2026 Systematix Institutional Research note, covered by Pharmacy Business, projected that the semaglutide generic India launch alone could lift overall Indian Pharmaceutical Market growth by 0.5 to 1 percentage point. The same note flagged that initial price erosion of 30 to 50 percent could deepen to 70 to 75 percent over the medium term as competition does its job.

Who Is Selling What, and at What Price?

The list of launches is now long enough that pharmacists in trade press have started calling it a “slum of brands.” A quick map of the most important moves:

Natco Pharma was first off the line, launching its multi-dose vial under brands Semanat and Semafull on 20 March 2026 (Day 1 of patent expiry). Sun Pharma launched Noveltreat (chronic weight management) and Sematrinity (type 2 diabetes) the next day, 21 March 2026, alongside Dr Reddy’s, Zydus, Glenmark, Alkem and Mankind. Dr Reddy’s Laboratories rolled out Obeda for diabetes, has guided to 12 million pens manufactured in year one, and is filing across 87 countries as patents fall sequentially. Zydus Lifesciences took a more differentiated route — a reusable multi-dose pen device, branded Semaglyn, Mashema and Alterme, at roughly ₹2,200 a month. Natco Pharma launched its multi-dose vial under two brand names — Semanat and Semafull — at Rs. 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml strengths and Rs. 1,750 for the 8 mg/3 ml strength, on 20 March 2026. Both Semanat and Semafull are vial-format brands; the pen-device version was scheduled for launch in April 2026 at Rs. 4,000–4,500 per month depending on strength. Glenmark’s GLIPIQ, available in vial and pre-filled pen, sits in the ₹1,300–1,760 range. Alkem priced its prefilled injection from ₹1,800.

For context: branded semaglutide retailed between ₹10,850 and ₹16,400 a month before patent expiry, and that was after Novo Nordisk preemptively cut prices by up to 37 percent in November 2025.

Other players in the mix include Mankind Pharma (Samakind), Lupin, Cipla, Torrent Pharma and Hetero — the last of which has already begun shipping to over 75 countries. Several launches went the partnership route: Eris Lifesciences with Natco, Ajanta Pharma with Biocon for Asian and African markets. Novo Nordisk has not gone quietly. The originator is hedging through co-marketing deals with Emcure (Wegovy under the Poviztra brand) and Abbott India (Ozempic under Extensior). It is a textbook play to defend brand equity against cheaper substitutes.

A Disease Base Big Enough to Justify the Numbers

The diabetes drug market India operates within is the second-largest in the world. The International Diabetes Federation’s 2025 Diabetes Atlas put the country’s adult diabetic population at 89.8 million — only China is bigger. The ICMR-INDIAB study has documented 254 million Indian adults with generalised obesity and 351 million with abdominal obesity. NFHS-5 data shows one in four Indians now lives with obesity, with prevalence having nearly doubled over fifteen years.

Demand has not been the constraint. Penetration has. Diabetologists quoted by CNBC have repeatedly noted that close to half their patient base would clinically benefit from GLP-1 therapy, yet only around 5 percent are actually on it. The block has always been price. Generic GLP-1 drugs in India at sub-₹2,000 monthly price points start to dismantle that block in a way the originator’s own discounting never quite managed.

What Could Go Wrong?

The opportunity carries real execution risk. Semaglutide is a 31-amino-acid peptide with a complex fatty-acid side chain. Making it at scale is genuinely hard — recombinant DNA processes, tight quality controls, end-to-end cold chain. Forty-plus brands in a single market guarantees consolidation. Players without published Phase III data or audited manufacturing track records will likely not survive the first regulatory action or pricing squeeze.

There is also the brand-equity question. Novo Nordisk has spent years building physician familiarity with Ozempic and Wegovy, and many endocrinologists have signalled they will wait a few quarters of generic real-world evidence before switching established patients. Counterfeits, a persistent feature of injectable categories in India, are another known risk that quality-tier manufacturers will need to actively police.

Bottom Line

The semaglutide patent expiry has handed Indian pharma a rare set-up , a high-growth therapeutic category, a globally recognised molecule, and a head start of nearly six years over the markets that ultimately matter most. Whether the full $6 billion lands depends on what Indian companies have always been good at: pricing discipline, manufacturing scale, and the patient grind of regulatory filings across dozens of geographies.

On current evidence, the industry has positioned itself at the front of the category that will define the next decade of metabolic medicine globally.

You can also join our community at LinkedIn, Instagram, and Twitter to stay updated.